Browse for free
← Back to deals
● LiveAcquire· SaaS· telehealth, healthcare

Modern at-home allergy immunotherapy that replaces years of in-office shots

First seen Sep 5, 2026 · last checked 16 hours ago

Open at Acquire ↗
Asking price
$2,899,611
Annual profit
$-91,869
Annual revenue
$2,230,471
Revenue multiple
1.30x rev
Monthly profit
$-7,656
Age
5 yrs

Confidence in this listing

Too little published to evaluate. Treat every figure as a claim.

42/100

What is documented
  • Trading for 5 years
  • Tracked here for 1 month(s)
What to ask about
  • Listed through a marketplace, figures as supplied
  • No profit figure

This scores the paperwork, not the business. Acquire: listed through a marketplace, figures as supplied. Always verify the figures with the seller before making an offer.

Overview

This is a national telehealth platform focused on physician-guided, at-home allergy immunotherapy via a subscription model, helping patients access long-term, disease-modifying treatment without frequent in-office visits, while operating a fully compliant infrastructure licensed across all 50 states with integrated clinical, pharmacy, and technology workflows that support durable recurring revenue through multi-year treatment durations, strong retention, and efficient customer acquisition, alongside a rapidly scaling B2B channel that enables medical practices to offer allergy treatment without added operational complexity in a large, underserved chronic-care market. Key Highlights ✅ Modern at-home allergy immunotherapy delivered through a subscription model with physician oversight ✅ Fully compliant infrastructure licensed across all 50 states with integrated clinical, pharmacy, and technology workflows ✅ Durable recurring revenue supported by multi-year treatment durations, strong retention, and efficient customer acquisition ✅ Rapidly scaling B2B channel that enables medical practices to offer allergy treatment without added operational complexity ✅ Scalable, capital-efficient platform serving a large, underpenetrated segment of chronic care with long-term growth potential

Price & status history

  1. ListedSep 5, 2026

Similar live deals